成纤维细胞生长因子受体抑制剂在肿瘤耐药中的研究进展  

Research progress of fibroblast growth factor receptor inhibitors in drug resistance of tumor

作　　者：辛铭 高奇 徐娟娟 李轩 贾秀芹[1] XIN Ming;GAO Qi;XU Juan-juan;LI Xuan;JIA Xiu-qin(Key Laboratory of Molecular Pharmacology,Liaocheng People's Hospital,Liaocheng SHANDONG 252000,China;Shandong First Medical University/Shandong Academy of Medical Sciences,Taian SHANDONG 271000,China)

机构地区：[1]聊城市人民医院分子药理学重点实验室,山东聊城252000 [2]山东第一医科大学/山东省医学科学院,山东泰安271000

出　　处：《中国新药与临床杂志》2022年第2期65-70,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：聊城市人民医院院级青年科研基金资助项目(LYQN2019020)。

摘　　要：抗肿瘤药物耐药性的产生是影响癌症患者预后的主要原因,因此临床上急需寻找一种提高药物敏感性、改善肿瘤耐药的新药物。在成纤维细胞生长因子受体(FGFR)信号异常活化而获得耐药潜能的肿瘤细胞中,FGFR抑制剂可通过阻断耐药蛋白的功能、抑制下游耐药相关信号通路的激活等多种机制来增强肿瘤细胞对抗癌药物(如化疗药、靶向药等)的敏感性,从而起到克服肿瘤耐药的作用。目前多个研究证实FGFR抑制剂不仅能改善药物转运蛋白介导的肿瘤化疗耐药,也能克服肿瘤对靶向药物表皮生长因子受体酪氨酸激酶抑制剂的耐药现象。The emergence of anti-tumor drug resistance is the main reason that affects the prognosis of cancer patients, so there is an urgent need to find a new drug that can improve drug sensitivity and improve tumor resistance in clinical practice. Abnormal activation of fibroblast growth factor receptor(FGFR) signals causes tumor resistance in tumor cells, FGFR inhibitors can enhance the sensitivity of tumor cells to anticancer drugs by blocking the function of drug-resistant proteins, inhibiting the activation of downstream drug resistance-related signaling pathways such as chemotherapeutics,targeted drugs, etc., thus playing a role in overcoming tumor resistance. At present, multiple studies have confirmed that FGFR inhibitors can not only improve drug transporter-mediated tumor chemotherapy resistance, but also overcome tumor resistance to the targeted drug epidermal growth factor receptor-tyrosine kinase inhibitor.

关 键 词：受体 成纤维细胞生长因子 蛋白酪氨酸激酶类 抗药性 肿瘤 改善肿瘤耐药 

分 类 号：R979.1[医药卫生—药品]